Anterior juxtascleral depot of anecortave acetate reduces IOP significantly

Article

IOP can be reduced significantly by an anterior juxtascleral depot of anecortave acetate, according to study results presented on a poster at this year's meeting of the Association for Research in Vision and Ophthalmology.

IOP can be reduced significantly by an anterior juxtascleral depot of anecortave acetate, according to study results presented on a poster at this year's meeting of the Association for Research in Vision and Ophthalmology.

Tiago S. Prata, MD conducted a prospective, non-randomized open-labelled trial on 25 eyes of uncontrolled glaucoma patients with a mean IOP of 30.9±9.2 mmHg. Dr Prata injected a single anterior juxtascleral depot of 30 mg of anecortave acetate and then assessed the eyes for the following three months. No major complications were recorded.

Mean IOP decreased to 20.9±7.5 mmHg at the first month. At the second month, IOP had increased slightly to 21.5±7.6 mmHg; in the third month, mean IOP dropped again to 19.1±5.2 mmHg.

Thus the researchers concluded that a single injection of anecortave acetate was sufficient to reduce IOP for a period of at least three months.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.